Isolation and functional identification of a novel human hepatic growth factor: Hepatopoietin Cn

Chun‐Ping Cui, Da‐Jin Zhang, Bing‐Xing Shi, Shao‐Jun Du, Dan‐Li Wu, Ping Wei, Gen‐Shen Zhong, Zi‐Kuan Guo, Yang Liu, Li‐Sheng Wang, Chu‐Tse Wu – 27 February 2008 – Hepatic stimulating substance (HSS) was first isolated from weanling rat liver in 1975 and found to stimulate hepatic DNA synthesis both in vitro and in vivo. Since then, mammalian and human HSS have been investigated for their potential to treat hepatic diseases. However, the essential nature in composition and structure of HSS remain puzzling because HSS has not been completely purified.

Activation‐induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma

Junji Komori, Hiroyuki Marusawa, Takafumi Machimoto, Yoko Endo, Kazuo Kinoshita, Tadayuki Kou, Hironori Haga, Iwao Ikai, Shinji Uemoto, Tsutomu Chiba – 27 February 2008 – Chronic inflammation plays a critical role in oncogenesis in various human organs. Epidemiological studies have demonstrated that patients with primary sclerosing cholangitis have a predisposition to develop cholangiocarcinoma (CC). However, the molecular mechanisms that account for the development of bile duct carcinomas are not well defined.

Impact of chronic liver disease and cirrhosis on health utilities using SF‐6D and the health utility index

Amy A. Dan, Jillian B. Kallman, Ragini Srivastava, Zahra Younoszai, Amy Kim, Zobair M. Younossi – 27 February 2008 – Assessment of health‐related quality of life (HRQL) and health utilities have become important aspects of clinical research. Patient‐derived utility adjustments are frequently used in economic analysis. Although HRQL has been frequently studied among patients with liver disease, extensive data on the health utilities of patients with liver disease are not available. Recently, SF‐6D has been developed to obtain utility scores from the widely used Short Form 36 questionnaire.

Comparison of histidine‐tryptophan‐ketoglutarate solution and University of Wisconsin solution in extended criteria liver donors

Richard S. Mangus, Jonathon A. Fridell, Rodrigo M. Vianna, Martin A. Milgrom, Paul Chestovich, Ray K. Chihara, A. Joseph Tector – 27 February 2008 – Liver, pancreas, and kidney allografts preserved in histidine‐tryptophan‐ketoglutarate (HTK) and University of Wisconsin (UW) solutions have similar clinical outcomes. This study compares HTK and UW in a large number of standard criteria donor (SCD) and extended criteria donor (ECD) livers at a single center over 5 years.

Removing patients from the liver transplant wait list: A survey of US liver transplant programs

Kevin P. Charpentier, Arun Mavanur – 27 February 2008 – Guidelines are in place regarding who is a candidate for liver transplantation. Once a potential candidate is listed, there are no uniform guidelines indicating when he should be removed from the list because of a change in clinical status. A survey with 14 scenarios was sent to the medical and surgical directors of all liver transplant programs in the United States. In each scenario, clinical information was provided about a patient active on the transplant wait list.

Subscribe to